A pragmatic single-blind randomised controlled trial and economic evaluation of the use of leukotriene receptor antagonists in primary care at steps 2 and 3 of the national asthma guidelines (ELEVATE study)

Health Technol Assess. 2011 May;15(21):1-132. doi: 10.3310/hta15210.
No abstract available

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adrenergic beta-2 Receptor Agonists / economics
  • Adrenergic beta-2 Receptor Agonists / therapeutic use
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Asthmatic Agents / economics*
  • Anti-Asthmatic Agents / therapeutic use
  • Asthma / drug therapy
  • Asthma / economics*
  • Asthma / psychology
  • Child
  • Confidence Intervals
  • Cost-Benefit Analysis
  • Disease Progression
  • Female
  • Health Status Indicators
  • Humans
  • Leukotriene Antagonists / economics*
  • Leukotriene Antagonists / therapeutic use
  • Male
  • Middle Aged
  • Practice Guidelines as Topic*
  • Primary Health Care / economics*
  • Psychometrics
  • Quality of Life / psychology
  • Quality-Adjusted Life Years
  • Single-Blind Method
  • Surveys and Questionnaires
  • Time Factors
  • Treatment Outcome
  • United Kingdom
  • Young Adult

Substances

  • Adrenergic beta-2 Receptor Agonists
  • Anti-Asthmatic Agents
  • Leukotriene Antagonists

Associated data

  • ISRCTN/ISRCTN99132811